Clinical study to assess the effectiveness of combined hepatoprotector FORSIVE

In April 2014, based on the Institute of Gastroenterology in Dnepropetrovsk, under the leadership of сhief specialist of NAMS of Ukraine in the area of gastroenterology and nutrition, vice-president of the NGO "Ukrainian gastroenterological Association", head of the gastroenterology Department and therapy of the of postgraduate education faculty of Dnipropetrovsk state medical Academy, honored doctor of Ukraine, doctor of medical science, professor Yury M. Stepanov - started a clinical study to assess the effectiveness of combined hepatoprotector FORCELIV in complex therapy of patients with liver disease of both infectious and non-infectious origin.

FORCELIV contains of 150 mg ademetionine. In addition to ademetionin contains arginine 90 mg, thioctic (α-lipoic) acid - 70 mg. All active ingredients are of natural origin. Thanks to enhanced formula FORCELIV is effective against such liver diseases as cirrhotic and pre-cirrhotic state, intrahepatic cholestasis, toxic and viral hepatitis.

Read the instructions for medical use of the drug FORCELIV you can at this link.